Plasmapheresis + Stem Cell Therapy
Documented synergy between Plasmapheresis and Stem Cell Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Plasma purification to rejuvenate the cellular environment
Definition and how it works: Plasmapheresis is a procedure in which the patient's blood is drawn, the plasma is separated from the blood cells via centrifugation and filtration, and the cells are reinfused with fresh plasma (albumin or young donor plasma). In the longevity context, it is used to remove pro-inflammatory factors that accumulate with ageing (TGF-β1, β2-microglobulin, VCAM-1) — termed 'rejuvenation-inhibiting factors' by researcher Irina Conboy.
Plasmapheresis is a procedure in which the patient's blood is drawn, the plasma is separated from the blood cells via centrifugation and filtration, and the cells are reinfused with fresh plasma (albumin or young donor plasma). In the longevity context, it is used to remove pro-inflammatory factors that accumulate with ageing (TGF-β1, β2-microglobulin, VCAM-1) — termed 'rejuvenation-inhibiting factors' by researcher Irina Conboy.
Origin and history
Medical plasmapheresis was developed in the 1960s to treat autoimmune diseases. Its application in longevity stems directly from Conboy's parabiosis studies and the research of startup Alkahest (acquired by Grifols) from 2014 onwards.
1. Haematological assessment Coagulation, calcium, renal and cardiac function. Extended informed consent.
2. Vascular access Central or large-bore peripheral venous access. Citrate anticoagulation.
3. Plasma separation Continuous centrifugation in a cell separator. Selective plasma extraction (1–1.5 plasma volumes).
4. Albumin replacement Reinfusion of cells with 5% human albumin or physiological saline. 2–4 hours total.
5. Post-procedure monitoring Calcium, blood pressure and symptom monitoring for 1–2 hours post-procedure. Same-day discharge if uneventful.
| Equipment | Brand / Model | Technical detail |
|---|---|---|
| Therapeutic cell separator | Fresenius Kabi COM.TEC / Haemonetics MCS+ | Continuous separation at 60–80 ml/min. Automatic alarms. Hospital standard. |
| Human albumin for replacement | Grifols Albutein / CSL Behring Albuminar | 4–5% solution for plasma replacement. Pharmaceutical GMP certification. |
Clinics on LongevityMap declare their exact equipment for objective scoring.
Plasma purification to rejuvenate the cellular environment
€800–2,500 per session
4–8 sessions in initial protocol; six-monthly maintenance
Prices vary by clinic, equipment and practitioner experience. LongevityMap compares price and quality so you always make the best decision.
Documented synergy between Plasmapheresis and Stem Cell Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between Plasmapheresis and NAD+ IV Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between Plasmapheresis and Exosome Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →We are collecting signed consents under GDPR Art. 9.2.a. First verified testimonials will appear once the first real clinics are onboarded (Q4 2026).
The Irina and Michael Conboy group (UC Berkeley) published in Nature (2005) that parabiosis (circulatory union of young and old mice) rejuvenated the old mouse's tissues. In 2022, they demonstrated that plasmapheresis (dilution of aged plasma) produced equivalent rejuvenation effects without needing young plasma. Clinical studies in Alzheimer's (AMBAR trial, Grifols) show slowed progression with periodic plasmapheresis.
2026 GeroScience (critical review): clinical translation of heterochronic plasma transfer for human systemic rejuvenation remains UNCERTAIN despite promising preclinical evidence (parabiosis, modulation of neuroinflammation/cognition). Critical of available human studies.
2026 Exp Mol Med: blood as mirror and modulator of aging. Multi-omics (proteomics, metabolomics, single-cell immunomics) show circulating components predict healthspan, longevity and disease risk. Blood components may modulate aging tempo.
2025 retrospective analysis: double filtration plasmapheresis (2 sessions for hypercholesterolemia/hyperlipoproteinemia(a)) modulates systemic immune-inflammatory indices derived from routine CBC. Implications for aging and low-grade inflammation.
2025 Br J Haematol: critical review explicitly identifying 'therapeutic plasma exchange for longevity' as unfounded intervention causing medical waste and patient harm. Framework to distinguish legitimate care from commercial claims.
Last bibliographic review: 2026-03-28.
Standard medical plasmapheresis removes a specific component (antibodies, LDL). Longevity plasmapheresis aims to dilute and remove pro-ageing factors from the plasma, replacing it with albumin or saline. They have different mechanisms.
The strongest human evidence is the AMBAR trial in Alzheimer's. In healthy individuals for longevity, the data are promising but primarily from animal models. Some centres in Spain and the US offer experimental protocols under extended informed consent.
Between 2 and 4 hours, similar to a dialysis session. The patient is seated or reclined with peripheral or central venous access. It is performed at medical centres with specialised staff.
Tell us your goal and budget. We cross-reference 500+ clinical parameters and generate 3 personalised plans with Plasmapheresis.
Generate My Protocol for freeLongevityMap content is for informational and educational purposes only. It does not constitute personalised medical advice. Always consult a healthcare professional before starting any treatment. Our team · Methodology